FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on BiomX (PHGE)
-
-
-
-
-
-
-
BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)
-
-
-
-
-
-
-
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates
-
-
-
-
-
-
-
BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections
-
-
-
-
-
-
-
BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Scie
-
-
-
-
-
-
-
BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation
-
-
-
-
-
-
-
BiomX Announces Dosing of First Subject in Phase 1a Study of BX002 Phage Therapy for Inflammatory Bowel Disease
-
322,094 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

